Marker Therapeutics (MRKR) Total Current Liabilities (2010 - 2026)

Marker Therapeutics (MRKR) has reported Total Current Liabilities for 17 consecutive years, with $2.4 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Total Current Liabilities fell 43.42% year-over-year to $2.4 million in Q2 2026; TTM through Jun 2026 was $2.4 million, a 43.42% decrease from a year earlier, with the FY2025 full-year figure at $2.3 million, down 34.36% from the prior year.
• Total Current Liabilities was $2.4 million for Q2 2026 at Marker Therapeutics, down from $3.6 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $13.5 million in Q2 2022 and troughed at $2.0 million in Q2 2024.
• A 5-year average of $4.7 million and a median of $3.4 million in 2024 frame the typical range for Total Current Liabilities.
• Across the five-year window, Total Current Liabilities soared 138.07% in 2022 and slumped 78.32% in 2023, its largest moves.
• Over 5 years, Total Current Liabilities stood at $7.8 million in 2022, then plunged by 60.49% to $3.1 million in 2023, then climbed by 12.67% to $3.5 million in 2024, then sank by 34.36% to $2.3 million in 2025, then grew by 6.41% to $2.4 million in 2026.
• The last three Total Current Liabilities figures came in at $2.4 million (Q2 2026), $3.6 million (Q1 2026), and $2.3 million (Q4 2025), per Business Quant data.